1. South Korea Stocks

  2. •

    Consumer Cyclical

  3. •

    Apparel - Manufacturers
Wellbiotec Co., Ltd.

Wellbiotec Co., Ltd.

010600.KS
Wellbiotec Co., Ltd.KR flagKorea Exchange
11.00
KRW
-4.00
- -
1.00BMarket Cap
Wellbiotec Co., Ltd.
010600.KS
(Korea Exchange)

Recent

price

11.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
9,870.48
8,651.94
10,464.27
11,233.19
10,795.53
8,264.83
7,359.59
5,604.58
4,639.69
3,704.58
1,258.88
1,721.6
1,862.8
2,460.99
753.84
1,051.82
911.53
Revenue per Share
-1,430
-1,280
138.17
-242
186
-459.78
36
-161
-573
-779.97
-368
-1,921
-572
-325
-819
-267.94
-206.39
Basic EPS, GAAP
-289.42
245.38
-388.64
183.35
56.81
-775.82
217.57
-285.26
-583.98
-536.97
-332.62
-198.87
-3.9
22.9
-66.25
-77.86
-0.5
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,574.31
2,416.89
-2,011.5
-2,111.35
-1,744.59
-1,956.33
-1,811.71
-1,984.94
-2,546.65
-2,399.56
-1,468.83
-3,497.61
-2,612.4
-1,071.56
-1,534.69
-1,766.48
-1,569.44
Book Value per Share
4,050.64
3,669.8
2,646.77
2,477.97
2,728.48
2,424.26
2,390.52
2,199.78
1,527.77
3,450.59
1,387.72
361.32
550.63
484.61
466.67
252.02
184.7
Tangible Book Value per Share
7
10
11
12
13
14
15
15
15
20
42
35
58
64
79
79
91
Basic Weighted Avg Shares
73,917
86,837
119,783
136,748
137,762
119,630
112,488
85,292
70,786
73,932
52,333
60,431
108,377
158,116
59,746
83,301
82,879
Sales/Revenue/Turnover
-1.88
1.77
4.77
2.35
1.41
0.14
1.85
-0.48
-7.25
-11.43
-12.32
-20.8
-3.99
1.43
-18.23
-3.45
-0.94
Operating Margin (%)
7,281
3,450
3,077
2,186
1,776
1,027
694
565
619
1,387
2,746
2,878
2,285
1,361
1,473
1,194
1,129
Depreciation Expense
-10,709
-12,847
1,582
-2,946
2,374
-6,655
550
-2,450
-8,742
-15,566
-15,298
-67,431
-33,279
-20,881
-64,910
-21,220
-18,766
Net Income, GAAP
- -
- -
29.12
- -
18.94
- -
63.9
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-14.49
-14.79
1.32
-2.15
1.72
-5.56
0.49
-2.87
-12.35
-21.05
-29.23
-111.58
-30.71
-13.21
-108.64
-25.47
-22.64
Profit Margin (%)
18,969
12,534
23,893
25,377
26,164
18,712
19,507
15,471
-12,834
37,427
39,506
-11,810
23,724
24,292
18,177
13,243
10,087
Working Capital
6,951
753
5,643
4,839
- -
650
650
- -
- -
100
123
8,684
735
603
1,697
966
691
LT Debt
32,439
37,639
39,676
36,040
40,689
35,121
36,573
33,858
26,850
76,402
75,636
19,491
37,029
35,303
37,220
20,184
17,386
Total Equity
- -
- -
7.81
- -
3.22
- -
1.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
16.34
- -
-21.72
- -
-6.24
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-48.22
-59.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
810
768
724
LT Borrowings
- -
- -
- -
LT Finance Leases
966
827
691
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
91
91
Market Capitalization
- -
- -
49,553

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
23,970
22,132
19,251
Cash, Cash Equivalents & STI
8,377
7,638
6,504
Accounts Receivable, Net
9,762
8,762
8,347
Inventories
- -
- -
- -
Total Current Liabilities
10,726
9,391
9,164
Payables & Accruals
- -
- -
- -
ST Debt
810
768
724
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.03%
-5.85%
-45.77%
Free Cash Flow
-153.97%
-266.81%
17.44%
Net Income, GAAP
7.6%
79.29%
-67.31%
Sales/Revenue/Turnover
4.6%
23.58%
39.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
19,698
26,133
25,212
-5,723
59,746
2024
20,353
24,033
23,060
18,571
83,301
2025
21,618
19,630
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-8
24
-33
- -
-819
2024
-22
-19
-59.63
- -
-267.94
2025
-6.42
-24.39
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Sabina Public Company Limited (SABINA.BK)
Hojeon Limited (111110.KS)
H & M Hennes & Mauritz AB (publ) (HMB.SW)
Shanghai Kai Kai Industry Company Limited (600272.SS)
Daidoh Limited (3205.T)
Ginegar Plastic Products Ltd. (GNGR.TA)
Business
Wellbiotec Co., Ltd. manufactures and sells leather products primarily for automotive, footwear, and fashion applications in South Korea and internationally. The company produces nappa, naked, soft, waterproof, gore-tex, nubuck, chrome, non-chrome, and grain leathers for handbags, shoes, car seats, steering wheels, handle covers, baseball gloves, and belts; it supplies these materials to brands including Coach, Tumi, Juicy, Victorinox, Brighton, Timberland, Foot Joy, Stride Rite, Honda, Acura, Suzuki, and Toyota. Wellbiotec also develops and sells medicines, health functional foods, protection products, diagnosis kits, and cosmeceuticals; provides logistics services such as consulting, transportation agency, customs clearance, insurance, and storage; and engages in import-export, rare earth minerals, EV chargers, polydeoxyribonucleotide substances extracted from salmon semen, and food and beverages businesses through subsidiaries. Founded in 1975 and headquartered at 5/F, Gyeongjin Building, 17 Yeongdong-daero 106-gil, Gangnam-gu, Seoul, South Korea, the company operates across logistics, bio, retail, and leather divisions with sales in South Korea, other regions, and previously China. Wellbiotec, formerly YBROAD Co., Ltd., agreed to acquire an additional 3.94% stake in Nokwon C&I Corp. from SPR Partners Co., Ltd. and Zeus Asset Management Co., Ltd.; it acquired 35 billion won worth of Geumyoung ENG and started a clean room business; and reported first-quarter 2025 earnings while cancelling a prior 2021 transaction.